Hodgkin's Lymphoma

Current Problems in Cancer

Volumn 30, Issue 3, 2006, Pages 107-158

  Tsang, Richard W ^a   Hodgson, David C ^a   Crump, Michael ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; IFOSFAMIDE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AMENORRHEA; ARTICLE; ATHEROSCLEROSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; AZOOSPERMIA; BLOOD TOXICITY; CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG FATALITY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FOLLOW UP; GENITAL SYSTEM; HEART ARRHYTHMIA; HODGKIN DISEASE; HUMAN; INFECTION; INFERTILITY; LEUKEMIA; LUNG TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MYELODYSPLASTIC SYNDROME; MYOCARDIAL DISEASE; NEUROPATHY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PATHOLOGY; PROGNOSIS; QUALITY OF LIFE; SIDE EFFECT; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

CLINICAL TRIALS; HODGKIN DISEASE; HUMANS;

EID: 33646883899     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2006.04.001     Document Type: Article

References (156)

1. American Cancer Society. Cancer facts and figures, 2006. Available from: http://www.cancer.org/docroot/stt/stt0.asp.
2. Miller T.P., LeBlanc M., Braziel R.M., Grogan T.M., Press O.W., and Fisher R.I. Was the bimodal age incidence of Hoddgkin's Lymphoma a result of mistaken diagnoses of non-Hodgkin's Lymphoma?. Blood 100 (2002) 771a
3. Hjalgrim H., Askling J., Rostgaard K., Hamilton-Dutoit S., Frisch M., Zhang J.S., et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 349 (2003) 1324-1332
4. Lukes R.J., and Butler J.J. The pathology and nomenclature of Hodgkin's disease. Cancer Res 26 (1966) 1063-1083
5. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid tissues (2001), IARC Press, Lyon, France
6. Howell S.J., Grey M., Chang J., Morgenstern G.R., Cowan R.A., Deakin D.P., et al. The value of bone marrow examination in the staging of Hodgkin's lymphoma. a review of 955 cases seen in a regional cancer centre. Br J Haematol 119 (2002) 408-411
7. Vinnicombe S.J., and Reznek R.H. Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 30 suppl 1 (2003) S42-S55
8. Greene F.L., Page D.L., Fleming I.D., Fritz A.G., Balch C.M., Haller D.G., et al. AJCC Cancer Staging Manual. 6th Edition (2002), Springer-Verlag, New York, NY
9. Lister T.A., Crowther D., Sutcliffe S.B., Glatstein E., Canellos G.P., Young R.C., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease. Cotswolds meeting. J Clin Oncol 7 (1989) 1630-1636
10. Wirth A., Seymour J.F., Hicks R.J., Ware R., Fisher R., Prince M., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 112 (2002) 262-268
11. Van Den Bossche B., Lambert B., De Winter F., Kolindou A., Dierckx R.A., Noens L., et al. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients. Nucl Med Commun 23 (2002) 1079-1083
12. Friedberg J.W., Fischman A., Neuberg D., Kim H., Takvorian T., Ng A.K., et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma. a blinded comparison. Leuk Lymphoma 45 (2004) 85-92
13. Feinstein A.R., Sosin D.M., and Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312 (1985) 1604-1608
14. UICC-International Union Against Cancer. TNM Classification of Malignant Tumours. 6th Edition (2002), Wiley-Liss, New York, NY
15. Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., and Tubiana M. Report of the Committee on Hodgkin's Disease staging classification. Cancer Res 31 (1971) 1860-1861
16. Kaplan H.S., and Rosenberg S.A. The treatment of Hodgkin's disease. Med Clin North Am 50 (1966) 1591-1610
17. Specht L. Prognostic factors in Hodgkin's disease. Cancer Treat Rev 18 (1991) 21-53
18. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339 (1998) 1506-1514
19. Diehl V., Sextro M., Franklin J., Hansmann M.L., Harris N., Jaffe E., et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease. report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 17 (1999) 776-783
20. Schlembach P.J., Wilder R.B., Jones D., Ha C.S., Fayad L.E., Younes A., et al. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J 8 (2002) 377-383
21. Crennan E., D'Costa I., Liew K.H., Thompson J., Laidlaw C., Cooper I., et al. Lymphocyte predominant Hodgkin's disease. a clinicopathologic comparative study of histologic and immunophenotypic subtypes. Int J Radiat Oncol Biol Phys 31 (1995) 333-337
22. Duhmke E., Franklin J., Pfreundschuh M., Sehlen S., Willich N., Ruhl U., et al. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease. long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19 (2001) 2905-2914
23. Engert A., Schiller P., Josting A., Herrmann R., Koch P., Sieber M., et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma. results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21 (2003) 3601-3608
24. Pappa V.I., Norton A.J., Gupta R.K., Wilson A.M., Rohatiner A.Z., Lister T.A., et al. Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. Ann Oncol 6 (1995) 559-565
25. Wilder R.B., Schlembach P.J., Jones D., Chronowski G.M., Ha C.S., Younes A., et al. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 94 (2002) 1731-1738
26. Nogova L., Reineke T., Eich H.T., Josting A., Muller-Hermelink H.K., Wingbermuhle K., et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma. a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16 (2005) 1683-1687
27. Wirth A., Yuen K., Barton M., Roos D., Gogna K., Pratt G., et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma. Cancer 104 (2005) 1221-1229
28. Ekstrand B.C., Lucas J.B., Horwitz S.M., Fan Z., Breslin S., Hoppe R.T., et al. Rituximab in lymphocyte-predominant Hodgkin disease. results of a phase 2 trial. Blood 101 (2003) 4285-4289
29. Peters M.V. Prophylactic treatment of adjacent areas in Hodgkin's disease. Cancer Res 26 (1966) 1232-1243
30. Vijayakumar S., and Myrianthopoulos L.C. An updated dose-response analysis in Hodgkin's disease. Radiother Oncol 24 (1992) 1-13
31. Loeffler M., Diehl V., Pfreundschuh M., Ruhl U., Hasenclever D., Nisters-Backes H., et al. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol 15 (1997) 2275-2287
32. Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma. new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol Suppl (2005) 90-97
33. Eich H., Mueller R., Engert A., Hanseman K., Skripnitchenko R., Pfistner B., et al. Comparison of 30 Gy versus 20 Gy involved field radiotherapy after two versus four cycles of ABVD in early stage Hodgkin's Lymphoma. Interim analysis of the German Hodgkin Study Group Trial HD10. Int J Radiat Oncol Biol Phys 63 suppl 1 (2005) S1
34. Koontz B.F., Kirkpatrick J.P., Clough R.W., Prosnitz R.G., Gockerman J.P., Moore J.O., et al. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease. cure balanced against complications. J Clin Oncol 24 (2006) 605-611
35. Eich H.T., Staar S., Gossmann A., Hansemann K., Skripnitchenko R., Kocher M., et al. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 58 (2004) 1121-1127
36. Gospodarowicz M.K., Sutcliffe S.B., Clark R.M., Dembo A.J., Fitzpatrick P.J., Munro A.J., et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone. Int J Radiat Oncol Biol Phys 22 (1992) 859-865
37. Hoskin P.J., Smith P., Maughan T.S., Gilson D., Vernon D., Syndikus I., et al. Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma. Clin Oncol (R Coll Radiol) 17 (2005) 47-53
38. Ng A.K., Bernardo M.P., Weller E., Backstrand K.H., Silver B., Marcus K.C., et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20 (2002) 2101-2108
39. Wirth A., Chao M., Corry J., Laidlaw C., Yuen K., Ryan G., et al. Mantle irradiation alone for clinical stage I-II Hodgkin's disease. long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol 17 (1999) 230-240
40. Backstrand K.H., Ng A.K., Takvorian R.W., Jones E.L., Fisher D.C., Molnar-Griffin B.J., et al. Results of a prospective trial of mantle irradiation alone for selected patients with early-stage Hodgkin's disease. J Clin Oncol 19 (2001) 736-741
41. Liao Z., Ha C.S., Vlachaki M.T., Hagemeister F., Cabanillas F., Hess M., et al. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease. long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 50 (2001) 971-977
42. Specht L., Gray R.G., Clarke M.J., Peto R., and International Hodgkin's Disease Collaborative Group. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease. a meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 16 (1998) 830-843
43. Ruffer J.U., Ballova V., Glossmann J., Sieber M., Franklin J., Nogova L., et al. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease. results of the German Hodgkin Study Group. Leuk Lymphoma 46 (2005) 1561-1567
44. Press O.W., LeBlanc M., Lichter A.S., Grogan T.M., Unger J.M., Wasserman T.H., et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 19 (2001) 4238-4244
45. Specht L. Very long-term follow-up of the Danish National Hodgkin Study Group's randomized trial of radiotherapy (RT) alone vs. combined modality treatment (CMT) for early stage Hodgkin Lymphoma, with special reference to second tumours and overall survival. Blood 102 (2003) 2351
46. Meerwaldt J.H., et al. Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favourable supradiagpragmatic clinical stages I-II Hodgkin's lymphoma. preliminary results of the EORTC-GELA H8-F randomized trial (#20931) in 543 patients. Leuk Lymphoma 42 (2001) 12
47. Bonadonna G., Bonfante V., Viviani S., Di Russo A., Villani F., Valagussa P., et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease. long-term results. J Clin Oncol 22 (2004) 2835-2841
48. Klasa R.J., Connors J.M., Gascoyne R.D., Hoskins P., Shenkier T., and Voss N. Brief Chemotherapy (CT) with involved field (IFRT) or extended field (EFRT) radiation after clinical staging (CS) are equivalent and both superior to EFRT alone following laparotomy staging (PS IA, IIA) in limited Hodgkin's lymphoma (HL). Leuk Lymphoma 42 S2 (2001) 51 Abstract p-087
49. Radford J.A., Williams M.V., Hancock B.W., Hoskin P., Sun-Mynt H., Smith P., et al. Minimal initial chemotherapy plus involved field radiotherapy (RT) vs. mnatle field RT for clinical IA/IIA supra-diaphragmatic Hodgkin's disease (HD). Eur J Haematol 73 suppl 65 (2004) 39
50. Tsang R.W., Gospodarowicz M.K., and O'Sullivan B. Staging and management of localized non-Hodgkin's lymphomas. variations among experts in radiation oncology. Int J Radiat Oncol Biol Phys 52 (2002) 643-651
51. Shakespeare T.P., and Holecek M.J. Defining involved field (IF) radiotherapy in Hodgkin's disease. Australas Radiol 42 (1998) 172
52. Horning S.J., Hoppe R.T., Breslin S., Bartlett N.L., Brown B.W., and Rosenberg S.A. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease. mature results of a prospective clinical trial. J Clin Oncol 20 (2002) 630-637
53. Raemaekers J., Kluin-Nelemans H., Teodorovic I., Meerwaldt C., Noordijk E., Thomas J., et al. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38 suppl 4 (2002) S107-S113
54. Canellos G.P., Anderson J.R., Propert K.J., Nissen N., Cooper M.R., Henderson E.S., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 (1992) 1478-1484
55. Duggan D.B., Petroni G.R., Johnson J.L., Glick J.H., Fisher R.I., Connors J.M., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease. report of an intergroup trial. J Clin Oncol 21 (2003) 607-614
56. Longo D.L. Radiation therapy in Hodgkin disease. why risk a Pyrrhic victory?. J Natl Cancer Inst 97 (2005) 1394-1395
57. Canellos G.P. Chemotherapy alone for early Hodgkin's lymphoma. an emerging option. J Clin Oncol 23 (2005) 4574-4576
58. Longo D.L., Glatstein E., Duffey P.L., Young R.C., Hubbard S.M., Urba W.J., et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease. seven-year results of a prospective randomized trial. J Clin Oncol 9 (1991) 906-917
59. Biti G.P., Cimino G., Cartoni C., Magrini S.M., Anselmo A.P., Enrici R.M., et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease. eight-year update of an Italian prospective randomized study. J Clin Oncol 10 (1992) 378-382
60. Pavlovsky S., Maschio M., Santarelli M.T., Muriel F.S., Corrado C., Garcia I., et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst 80 (1988) 1466-1473
61. Nachman J.B., Sposto R., Herzog P., Gilcrest G.S., Wooden S.L., Thomson J., et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20 (2002) 3765-3771
62. Meyer R.M., Gospodarowicz M.K., Connors J.M., Pearcey R.G., Bezjak A., Wells W.A., et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma. National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23 (2005) 4634-4642
63. Straus D.J., Portlock C.S., Qin J., Myers J., Zelenetz A.D., Moskowitz C., et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104 (2004) 3483-3489
64. Cosset J.M., Henry-Amar M., Pellar-Cosset B., Carde P., Girinski T., Tubiana M., et al. Pericarditis and myocardial infarction after Hodgkin's disease therapy. Int J Radiat Oncol Biol Phys 21 (1991) 447-449
65. Cosset J.M., Ferme C., Eghbali H., et al. MOPP/ABV hybrid and irradiation in unfavourable supradiaphragmatic clinical stages I-II Hodgkin's lymphoma. preliminary results of the EORTC-GELA H8-U randomized trial (# 20931) in 995 patients. Leuk Lymphoma 42 (2001) 12
66. Diehl V., Brillant C., Engert A., Wolf J., Nogova L., Mueller R.P., et al. Intensification of chemotherapy and concomitant reduction of radiotherapy dose in intermediate stage Hodgkin's lymphoma. results of the fourth interim analysis of the HD 11 trial of the GHSG. Eur J Haematol 73 suppl 65 (2004) 37
67. Gobbi P.G., Levis A., Chisesi T., Broglia C., Vitolo U., Stelitano C., et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma. final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23 (2005) 9198-9207
68. Canellos G.P., and Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 346 (2002) 1417-1418
69. Connors J.M., Klimo P., Adams G., Burns B.F., Cooper I., Meyer R.M., et al. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD. a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 15 (1997) 1638-1645
70. Hancock B.W., Gregory W.M., Cullen M.H., Hudson G.V., Burton A., Selby P., et al. ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease. results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. Br J Cancer 84 (2001) 1293-1300
71. Johnson P.W., Radford J.A., Cullen M.H., Sydes M.R., Walewski J., Jack A.S., et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma. results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 23 (2005) 9208-9218
72. Diehl V., Franklin J., Pfreundschuh M., Lathan P., Paulus U., Hasenclever D., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 (2003) 2386-2395
73. Diehl V., Schiller P., Engert A., Wolf J., Josting A., Mueller R., et al. Results of the third interim analysis of the HD12 trial of the GHSG. eight courses of escalated BEACOPP versus 4 escalated and 4 baseline courses of BEACOPP with or without additive radiotherapy for advanced stage Hodgkin s Lymphoma. Blood 102 (2003) 85
74. Straus D.J., Gaynor J.J., Myers J., Merke D.P., Caravelli J., Chapman D., et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 8 (1990) 1173-1186
75. Federico M., Bellei M., Brice P., Brugiatelli M., Nagler A., Gisselbrecht C., et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 21 (2003) 2320-2325
76. Engert A., Ballova V., Haverkamp H., Pfistner B., Josting A., Duhmke E., et al. Hodgkin's lymphoma in elderly patients. a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 23 (2005) 5052-5060
77. Ballova V., Ruffer J.U., Haverkamp H., Pfistner B., Muller-Hermelink H.K., Duhmke E., et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16 (2005) 124-131
78. Aleman B.M., Raemaekers J.M., Tirelli U., Bortolus R., van 't Veer M.B., Lybeert M.L., et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348 (2003) 2396-2406
79. Loeffler M., Brosteanu O., Hasenclever D., Sextro M., Assouline D., Bartolucci A.A., et al., International Database on Hodgkin's Disease Overview Study Group. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 16 (1998) 818-829
80. Laskar S., Gupta T., Vimal S., Muckaden M.A., Saikia T.K., Pai S.K., et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy. is there a need?. J Clin Oncol 22 (2004) 62-68
81. Diehl V. Chemotherapy or combined modality treatment. the optimal treatment for Hodgkin's disease. J Clin Oncol 22 (2004) 15-18
82. Ferme C., Sebban C., Hennequin C., Divine M., Lederlin P., Gabarre J., et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease. results of the groupe d'etudes des lymphomes de l'Adulte H89 trial. Blood 95 (2000) 2246-2252
83. Brice P., Colin P., Berger F., de Kerviler E., Divine M., Bouaffia F., et al. Advanced Hodgkin disease with large mediastinal involvement can be treated with eight cycles of chemotherapy alone after a major response to six cycles of chemotherapy. a study of 82 patients from the Groupes d'Etudes des Lymphomes de l'Adulte H89 trial. Cancer 92 (2001) 453-459
84. Fabian C.J., Mansfield C.M., Dahlberg S., Jones S.E., Miller T.P., Van Slyck E., et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med 120 (1994) 903-912
85. Horning S.J., Williams J., Bartlett N.L., Bennett J.M., Hoppe R.T., Neuberg D., et al. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease. Eastern Cooperative Oncology Group Pilot Study E1492. J Clin Oncol 18 (2000) 972-980
86. Josting A., Franklin J., May M., Koch P., Beykirch M.K., Heinz J., et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 20 (2002) 221-230
87. Josting A., Rueffer U., Franklin J., Sieber M., Diehl V., and Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma. a report from the German Hodgkin Lymphoma Study Group. Blood 96 (2000) 1280-1286
88. Lancet J.E., Rapoport A.P., Brasacchio R., Eberly S., Raubertas R.F., Linder T., et al. Autotransplantation for relapsed or refractory Hodgkin's disease. long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 22 (1998) 265-271
89. Crump M., Smith A.M., Brandwein J., Coutere F., Sherret H., Sutton D.M.C., et al. High-dose Etoposide and Melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease. Importance of disease status at transplant. J Clin Oncol 11 (1993) 704-711
90. Moskowitz C.H., Kewalramani T., Nimer S.D., Gonzalez M., Zelenetz A.D., and Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 124 (2004) 645-652
91. Lazarus H.M., Rowlings P.A., Zhang M.J., Vose J.M., Armitage J.O., Bierman P.J., et al. Autotransplants for Hodgkin's disease in patients never achieving remission. a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17 (1999) 534-545
92. Constans M., Sureda A., Terol M.J., Arranz R., Caballero M.D., Iriondo A., et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease. results and clinical variables affecting outcome. Ann Oncol 14 (2003) 745-751
93. Bonfante V., Santoro A., Viviani S., Devizzi L., Balzarotti M., Soncini F., et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 15 (1997) 528-534
94. Andre M., Henry-Amar M., Pico J.L., Brice P., Blaise D., Kuentz M., et al., Societe Francaise de Greffe de Moelle. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure. a case-control study. J Clin Oncol 17 (1999) 222-229
95. Linch D.C., Winfield D., Goldstone A.H., Moir D., Hancock B., McMillan A., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease. results of a BNLI randomised trial. Lancet 341 (1993) 1051-1054
96. Schmitz N., Pfistner B., Sextro M., Sieber M., Carella A.M., Hanel M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease. a randomised trial. Lancet 359 (2002) 2065-2071
97. Sureda A., Constans M., Iriondo A., Arranz R., Caballero V.D., Vidal M.J., et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 16 (2005) 625-633
98. Moskowitz C.H., Nimer S.D., Zelenetz A.D., Trippett T., Hedrick E.E., Filippa D.A., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease. analysis by intent to treat and development of a prognostic model. Blood 97 (2001) 616-623
99. Josting A., Rudolph C., Reiser M., Mapara M., Sieber M., Kirchner H.H., et al. Time-intensified dexamethasone/cisplatin/cytarabine. an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 13 (2002) 1628-1635
100. Josting A., Rudolph C., Mapara M., Glossmann J.P., Sienawski M., Sieber M., et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma. results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 16 (2005) 116-123
101. Santoro A., Bredenfeld H., Devizzi L., Tesch H., Bonfante V., Viviani S., et al. Gemcitabine in the treatment of refractory Hodgkin's disease. results of a multicenter phase II study. J Clin Oncol 18 (2000) 2615-2619
102. Zinzani P.L., Bendandi M., Stefoni V., Albertini P., Gherlinzoni F., Tani M., et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 85 (2000) 926-929
103. Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., and Peters G.J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2 (1996) 521-530
104. Baetz T., Belch A., Couban S., Imrie K., Yau J., Myers R., et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease. a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 14 (2003) 1762-1767
105. Kuruvilla J., Nagy T., Pintilie M., Tsang R., Keating A., and Crump M. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 106 (2006) 353-360
106. Mundt A.J., Sibley G., Williams S., Hallahan D., Nautiyel J., and Weichselbaum R.R. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys 33 (1995) 261-270
107. Pezner R.D., Lipsett J.A., Vora N., and Forman S.J. Radical radiotherapy as salvage treatment for relapse of Hodgkin's disease initially treated by chemotherapy alone. prognostic significance of the disease-free interval. Int J Radiat Oncol Biol Phys 30 (1994) 965-970
108. Wirth A., Corry J., Laidlaw C., Matthews J., and Liew K.H. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 39 (1997) 599-607
109. Josting A., Nogova L., Franklin J., Glossmann J.P., Eich H.T., Sieber M., et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma. a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 23 (2005) 1522-1529
110. Campbell B., Wirth A., Milner A., Di Iulio J., MacManus M., and Ryan G. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure. Int J Radiat Oncol Biol Phys 63 (2005) 1538-1545
111. O'Brien P.C., and Parnis F.X. Salvage radiotherapy following chemotherapy failure in Hodgkin's disease. what is its role?. Acta Oncol 34 (1995) 99-104
112. Yahalom J. Integrating radiotherapy into bone marrow transplantation programs for Hodgkin's disease. Int J Radiat Oncol Biol Phys 33 (1995) 525-528
113. Yahalom J., Gulati S.C., Toia M., Maslak P., McCarron E.G., O'Brien J.P., et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 11 (1993) 1062-1070
114. Tsang R.W., Gospodarowicz M.K., Sutcliffe S.B., Crump M., Keating A., PMH Lymphoma Group, and Toronto Autologous BMT Group. Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. Eur J Cancer 35 (1999) 73-78
115. Poen J.C., Hoppe R.T., and Horning S.J. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease. The impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys 36 (1996) 3-12
116. Rapoport A.P., Meisenberg B., Sarkodee-Adoo C., Fassas A., Frankel S.R., Mookerjee B., et al. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 29 (2002) 303-312
117. Dawson L.A., Saito N.G., Ratanatharathorn V., Uberti J.P., Adams P.T., Ayash L.J., et al. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease. Int J Radiat Oncol Biol Phys 59 (2004) 208-218
118. Wadhwa P., Shina D.C., Schenkein D., and Lazarus H.M. Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation?. Bone Marrow Transplant 29 (2002) 183-189
119. Wirth A., Prince H.M., Wolf M., Stone J.M., Matthews J., Gibson J., et al. Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas. a prospective Australasian Leukaemia and Lymphoma Group Study. Bone Marrow Transplant 35 (2005) 291-298
120. Bolwell B.J., Kalaycio M., Goormastic M., Dannley R., Andresen S.W., Lichtin A., et al. Progressive disease after ABMT for Hodgkin's disease. Bone Marrow Transplant 20 (1997) 761-765
121. Mundt A.J., Connell P.P., and Mansur D.B. What is the optimal treatment volume in Hodgkin's disease patients undergoing high-dose chemotherapy and adjuvant radiation therapy?. Radiat Oncol Investig 7 (1999) 353-359
122. Hodgson D.C., Zhang-Salomons J., Rothwell D., Paszat L.F., Tsang R.W., Crump M., et al. Evolution of treatment for Hodgkin's disease. a population-based study of radiation therapy use and outcome. Clin Oncol (R Coll Radiol) 15 (2003) 255-263
123. Aleman B.M., van den Belt-Dusebout A.W., Klokman W.J., Van't Veer M.B., Bartelink H., and van Leeuwen F.E. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21 (2003) 3431-3439
124. Travis L.B., Hill D., Dores G.M., Gospodarowicz M., van Leeuwen F.E., Holowaty E., et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97 (2005) 1428-1437
125. Travis L.B., Gospodarowicz M., Curtis R.E., Clarke E.A., Andersson M., Glimelius B., et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94 (2002) 182-192
126. Glanzmann C., Kaufmann P., Jenni R., et al. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 46 (1998) 51-62
127. Boivin J.F., Hutchison G.B., Lubin J.H., and Mauch P. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 69 (1992) 1241-1247
128. Hancock S.L., and Hoppe R.T. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 6 (1996) 225-242
129. Hancock S.L., Tucker M.A., and Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. J Am Med Assoc 270 (1993) 1949-1955
130. King V., Constine L.S., Clark D., Schwartz R.G., Muhs A.G., Henzler M., et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease. Int J Radiat Oncol Biol Phys 36 (1996) 881-889
131. Hull M.C., Morris C.G., Pepine C.J., and Mendenhall N.P. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. J Am Med Assoc 290 (2003) 2831-2837
132. Chronowski G.M., Wilder R.B., Tucker S.L., Ha C.S., Yoanes A., Fayad L., et al. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. Int J Radiat Oncol Biol Phys 55 (2003) 36-43
133. Reinders J.G., Heijmen B.J., Olofsen-van Acht M.J., van Putten W.L., and Levendag P.C. Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up. Radiother Oncol 51 (1999) 35-42
134. Heidenreich P.A., Hancock S.L., Lee B.K., Mariscal C.S., and Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol 42 (2003) 743-749
135. Adams M.J., Lipsitz S.R., Colan S.D., Tarbell N.J., Treves S.T., Diller L., et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol 22 (2004) 3139-3148
136. Zinzani P.L., Gherlinzoni F., Piovaccari G., Bendandi M., Ferretti R.M., et al. Cardiac injury as late toxicity of mediastinal radiation therapy for Hodgkin's disease patients. Haematologica 81 (1996) 132-137
137. Kulkarni S.S., Sastry P.S., Saikia T.K., Parikh P.M., Gopal R., and Advani S.H. Gonadal function following ABVD therapy for Hodgkin's disease. Am J Clin Oncol 20 (1997) 354-357
138. Bonadonna G., Santoro A., Viviani S., Lombardi C., and Ragni G. Gonadal damage in Hodgkin's disease from cancer chemotherapeutic regimens. Arch Toxicol Suppl 7 (1984) 140-145
139. Behringer K., Breuer K., Reineke T., May M., Nogova L., Klimm B., et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy. a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 23 (2005) 7555-7564
140. Kornblith A.B., Anderson J., Cella D.F., Tross S., Zuckerman E., Cherin E., et al. Comparison of psychosocial adaptation and sexual function of survivors of advanced Hodgkin disease treated by MOPP, ABVD, or MOPP alternating with ABVD. Cancer 70 (1992) 2508-2516
141. Kornblith A.B., Anderson J., Cella D.F., Tross S., Zuckerman E., Cherin E., et al., The Cancer and Leukemia Group B. Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. Cancer 70 (1992) 2214-2224
142. Joly F., Henry-Amar M., Arveux P., Remen O., Tanguy A., Peny A.M., et al. Late psychosocial sequelae in Hodgkin's disease survivors. a French population-based case-control study. J Clin Oncol 14 (1996) 2444-2453
143. Loge J.H., Abrahamsen A.F., Ekeberg O., and Kaasa S. Reduced health-related quality of life among Hodgkin's disease survivors. a comparative study with general population norms. Ann Oncol 10 (1999) 71-77
144. Greil R., Holzner B., Kemmler G., Kopp M., Buchowski A., Oberaigner W., et al. Retrospective assessment of quality of life and treatment outcome in patients with Hodgkin's disease from 1969 to 1994. Eur J Cancer 35 (1999) 698-706
145. Oldervoll L.M., Kaasa S., Knobel H., and Loge J.H. Exercise reduces fatigue in chronic fatigued Hodgkins disease survivors. results from a pilot study. Eur J Cancer 39 (2003) 57-63
146. Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17 (1999) 1244-1253
147. Jerusalem G., Hustinx R., Beguin Y., and Fillet G. Positron emission tomography imaging for lymphoma. Curr Opin Oncol 17 (2005) 441-445
148. Kazama T., Faria S.C., Varavithya V., Phongkitkarun S., Ito H., and Macapinlac H.A. FDG PET in the evaluation of treatment for lymphoma. clinical usefulness and pitfalls. Radiographics 25 (2005) 191-207
149. Castellucci P., Zinzani P., Nanni C., Farsad M., Moretti A., Alinari L., et al. 18F-FDG PET early after radiotherapy in lymphoma patients. Cancer Biother Radiopharm 19 (2004) 606-612
150. Rigacci L., Castagnoli A., Dini C., Carpaneto A., Matteini M., Alterini R., et al. (18)FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma. Long-term results. Oncol Rep 14 (2005) 1209-1214
151. National Comprehensive Cancer Network (NCCN). The NCCN Clinical Practice Guidelines in Oncology. Hodgkin's Disease. 2004. Available from: http://www.nccn.org.
152. Radford J.A., Eardley A., Woodman C., and Crowther D. Follow up policy after treatment for Hodgkin's disease. too many clinic visits and routine tests? A review of hospital records. Br Med J 314 (1997) 343-346
153. Torrey M.J., Poen J.C., and Hoppe R.T. Detection of relapse in early-stage Hodgkin's disease. role of routine follow-up studies. J Clin Oncol 15 (1997) 1123-1130
154. Dryver E.T., Jernstrom H., Tompkins K., Buckstein R., and Imrie K.R. Follow-up of patients with Hodgkin's disease following curative treatment. the routine CT scan is of little value. Br J Cancer 89 (2003) 482-486
155. Jerusalem G., Beguin Y., Fassotte M.F., Belhocine T., Hustinx R., Rigo P., et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 14 (2003) 123-130
156. Hutchings M., Loft A., Hansen M., Pedersen L.M., Buhl T., Jurlander J., et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107 (2006) 52-59